Is $NKTR the Most Undervalued Biotech Nobody's Talking About? (E129)

200 million eczema sufferers. A leading drug that fails more than half of them. A cancer-causing alternative that still projects $5 billion in sales. And a tiny 60-person San Francisco biotech that may have cracked the code — with a Nobel Prize-validated mechanism the market is somehow pricing at near-zero. This week, Krzysztof goes full deep-dive on Nectar Therapeutics ($NKTR), while Luke — self-confessed biotech skeptic — has the options chain open and his wallet ready.

📊 Why the world's most common skin disease has NO good cure yet — and why that $50B market opportunity is hiding in plain sight

💊 The cancer-warning drug that still projects $3–5B in revenue: what that tells you about how desperate patients really are

🎓 Res-peg explained without the jargon: the Nobel Prize-backed immune reset mechanism that makes $NKTR different from every other AD drug on the market

💀 The 33% single-day crash that Monkey calls 'borderline irrational' — and why buying that dip may have been one of the most logical trades of the year

🎯 Bull, base, and bear: a $240–$320 price target vs. today's ~$82 — and the position sizing rules that keep this from becoming a gamble

🧠 Why the market can't walk and chew gum: how $NKTR's alopecia data confusion is creating a 'free call option' that most investors are completely missing

🌐 The imminent April catalyst that could reprice this stock overnight — and why Monkey says a negative surprise would be the real shock

Sources: Adam May (biotech investor): https://x.com/A_May_MD

Segments: 00:00:00 The Disease Affecting 200 Million People With No Real Cure 00:05:00 What Is Atopic Dermatitis (Eczema) — And Why It's a $50B Market 00:10:00 Why the Best Drug on the Market Only Works for Half of Patients 00:15:00 The Cancer-Warning Drug Still Projecting $5B in Sales 00:20:00 $NKTR's Res-Peg: The Nobel Prize-Backed Mechanism Explained 00:27:00 The Phase 2 Data That Sent $NKTR From $6 to $80 00:33:00 The Alopecia Trial Disaster — And Why Monkey Says the Market Overreacted 00:43:00 Valuation Deep Dive: Is $NKTR Worth 4x From Here? 00:48:00 Upcoming Catalysts: What to Watch in April 2025 and Beyond 00:54:00 Position Sizing in Biotech — How Much Is Too Much? 01:01:00 Options Strategy for $NKTR: Calls vs. Shares vs. Selling Puts

********** SUPPORT THE SHOW AND BECOME A PATREON: wallstreetwildlife.com ********** Follow us at: ⁠⁠x.com/7LukeHallard ⁠x.com/7FlyingPlatypus ********** Fiscal.AI is the Complete Stock Research Platform for fundamental investors. With its beautiful design and institutional-quality data, Fiscal AI is incredibly powerful and easy to use. Get 15% off any premium plan with: fiscal.ai/wildlife ********** Monkey’s “Zen, Nietzsche, How to Live” Substack: firephilosophy.substack.com ********** To use the same portfolio tracking tool as Luke, check-out: portseido.com/?fpr=lukehallard ********** Disclosure: Wall Street Wildlife hosts and guests are not financial advisors, and nothing they say on this show is formal advice or a recommendation ********** Fed up with the stock market giving you a hard time?

- Invest like seasoned pros with over 40 years in the game - Discover the world's leading companies - Sharpen your best investing practices and ditch the worst - Learn how to start investing - Essential investing principles to boost your returns